CN105949266A - Withana lactide compound, method for extracting same and application of withana lactide compound - Google Patents
Withana lactide compound, method for extracting same and application of withana lactide compound Download PDFInfo
- Publication number
- CN105949266A CN105949266A CN201610341609.4A CN201610341609A CN105949266A CN 105949266 A CN105949266 A CN 105949266A CN 201610341609 A CN201610341609 A CN 201610341609A CN 105949266 A CN105949266 A CN 105949266A
- Authority
- CN
- China
- Prior art keywords
- fraction
- volume ratio
- compound
- obtains
- methanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
Abstract
The invention discloses a withana lactide compound, a method for extracting the same and application of the withana lactide compound. The withana lactide compound is of a structure shown as a formula (I). The withana lactide compound, the method and the application have the advantages that release of nitric oxide (NO) can be effectively inhibited by the withana lactide compound, and accordingly the withana lactide compound can be used as an anti-inflammatory medicine.
Description
Technical field
The present invention relates to field of traditional Chinese medicine extraction, relate to a kind of withanolide compounds, extracting method and application.
Background technology
Bitter (Physalis angulata L.), also known as Fructus Seu Herba Pubescentis, Herba seu Fructus Physalis Minimae, Herba seu Fructus Physalis Minimae, Piao Piaocao, beats volume bubble etc., for eggplant
Section (Solanaceae) Physalis (Physalis) annual herb plant." Luchuan book on Chinese herbal medicine " and " China's book on Chinese herbal medicine " is to hardship
Medicinal efficacy has detailed record, and hardship has circulation of qi promoting, relieving distension, diuresis, controls abdominal distention, heat-clearing and toxic substances removing, and diuresis is stopped blooding, disappeared
Swollen eliminating stagnation, can be used for treating laryngopharynx swelling and pain, lung abscess, parotitis；Dysuria, hematuria gingival swelling and pain, the disease such as pemphigus.
Among the people being used for treats the diseases such as bleb skin ulcer, gingival swelling and pain, jaundice due to damp-heat, red swelling and pain of throat, cough due to lung-heat.Chinese scholars
Antiinflammatory (Choi, the E.M. of hardship is confirmed by In vitroandin vivotrial；et al.Investigations of anti-inflammatory
and antinociceptive activities of Piper cubeba,Physalis angulata and Rosa hybrida.Journal of
Ethnopharmacology 2003,89,171 175.), antitumor (He, H.；et al.Physalin A induces apoptotic cell
death and protective autophagy in HT1080human fibrosarcoma cells.Journal of Natural Products,
2013,76,880 888.), antibacterial (Silva, M.T.G.；et al.Studies on antimicrobial activity,in vitro,of
Physalis angulata L.(Solanaceae)fraction and physalin B bringing out the importance of assay
Determination.Memorias do Instituto Oswaldo Cruz 2005,100,779 782.), antioxidation (Choi, E.M.；
et al.Effect of some medicinal plants on plasma antioxidant system and lipid levels in rats.
Phytotherapy research.2005,19,382-386.) etc. effect.
But there is not been reported to extract withanolide compounds, extracting method and application from hardship.
Summary of the invention
It is an object of the invention to provide withanolide compounds.
Second object of the present invention is to provide the extracting method of withanolide compounds.
Third object of the present invention is to provide the application of withanolide compounds.
Fourth object of the present invention is to provide the bitter extract of the withanolide compounds comprising claim 1 and 2.
5th purpose of the present invention is to provide the application of bitter extract.
6th purpose of the present invention is to provide the pharmaceutical composition containing withanolide compounds.
7th purpose of the present invention is to provide the application of aforementioned pharmaceutical compositions.
Technical scheme is summarized as follows:
Withanolide compounds, has a structure of formula (I):
Wherein:
R1For OH or OCH3；
R2For OH or H；
R3For OH or OAc；
R4For H；R5For H or OH；Or R4And R5For
R6For H or OH.
Above-claimed cpd, preferred structural formula is:
The extracting method of above-claimed cpd, comprises the steps:
(1) with bitter dry stem and leaf as raw material, the volume fraction adding raw material 8-10 mass times is 60%-80% ethanol water,
Reflux, extract, 2-3 time, extracts 2-3 hour every time, merges and obtains extracting solution, decompression and solvent recovery, obtains total extractum after concentration；
(2) total extractum is distributed in the water of 5-10 mass times, extracts by petroleum ether and ethyl acetate successively, ethyl acetate
Extract decompression and solvent recovery, obtains ethyl acetate layer extractum；
(3) ethyl acetate layer extractum separates through silica gel column chromatography, is respectively the two of 100:1,50:1,30:1 and 15:1 with volume ratio
Chloromethanes-methanol is eluent gradient eluting, obtains fraction Fr.1, Fr.2, Fr.3 and Fr.4；
(4) fraction Fr.3 separates through silica gel column chromatography, with the petroleum ether-acetone of volume ratio respectively 10:1,8:1 and 6:1 for washing
De-agent gradient elution, obtains fraction Fr.3-1, Fr.3-2, Fr.3-3；
(5) fraction Fr.3-3 is through Sephadex LH-20 pillar layer separation, and the methylene chloride-methanol with volume ratio as 1:1 is as eluant
Isocratic elution, obtains fraction Fr.3-3-1 and Fr.3-3-2；
(6) fraction Fr.3-3-2 is through ODS pillar layer separation, and with volume ratio as 1:9, the methanol-water of 3:7,5:5 and 8:2 is as eluting
Agent gradient elution, obtains fraction Fr.3-3-2-1, Fr.3-3-2-2, Fr.3-3-2-3 and Fr.3-3-2-4；
(7) fraction Fr.3-3-2-4 separates through silica gel preparative thin layer chromatography, and the dichloromethane-acetone with volume ratio as 1:1 is for launching
Agent is prepared, and obtains compound 2；
(8) fraction Fr.4 separates through silica gel column chromatography, with volume ratio as 80:1, the chloroform of 40:1,20:1,10:1 and 5:1-
Acetone is eluent gradient eluting, obtains fraction Fr.4-1, Fr.4-2, Fr.4-3, Fr.4-4 and Fr.4-5；
(9) fraction Fr.4-2 is through preparing HPLC chromatogram, and the methanol-water with volume ratio as 7:3 is flowing phase, is purified,
Obtain compound 4；
(10) fraction Fr.4-4 is through preparing HPLC chromatogram, and the methanol-water with volume ratio as 7:3 is flowing phase, is purified,
Obtain compound 5；
(11) fraction Fr.4-5 is flowing phase through ODS pillar layer separation, the methanol-water with volume ratio as 7:3, is purified,
Obtain fraction Fr.4-5-1, Fr.4-5-2；
(12) fraction Fr.4-5-2 is through preparing HPLC chromatogram, and the methanol-water with volume ratio as 7:3 is flowing phase, is purified,
Obtain compound 1 and compound 3.
The application in preparation suppression cell release NO medicine of the withanolide compounds.
Comprise the bitter extract of withanolide class.
The application in preparation suppression cell release NO medicine of the bitter extract.
A kind of pharmaceutical composition, is to comprise withanolide compounds or its pharmaceutically acceptable salt, and pharmaceutically acceptable
Carrier and/or excipient.
Aforementioned pharmaceutical compositions application in preparation suppression cell release NO medicine.
Advantages of the present invention:
The withanolide compounds of the present invention can suppress the release of nitric oxide (NO) effectively, and prompting the compounds of this invention can
Medicine as antiinflammatory.
Detailed description of the invention
Being described technical scheme below in conjunction with specific embodiment, described embodiment is only the present invention one
Section Example rather than whole embodiments.Based on the embodiment in the present invention, those of ordinary skill in the art are not making
Go out the every other embodiment obtained under creative work premise, broadly fall into the scope of protection of the invention.
Embodiment 1
The extracting method of withanolide compounds, comprises the steps:
(1) with the dry stem and leaf (9.5kg) of bitter (Physalis angulata L.) as raw material, raw material 9 mass times is added
Volume fraction is 75% ethanol water, reflux, extract, 2 times, extracts 2 hours every time, merges and obtains extracting solution, and recovered under reduced pressure is molten
Agent, obtains total extractum (1370g) after concentration；
(2) total extractum is distributed in the water of 5 mass times, extracts with equal-volume petroleum ether and ethyl acetate successively, acetic acid
Ethyl ester extract decompression and solvent recovery, obtains ethyl acetate layer extractum 116g；
(3) ethyl acetate layer extractum separates through silica gel column chromatography, is respectively the two of 100:1,50:1,30:1 and 15:1 with volume ratio
Chloromethanes-methanol is eluent gradient eluting, obtains fraction Fr.1, Fr.2, Fr.3 (35g) and Fr.4 (15g)；
(4) fraction Fr.3 separates through silica gel column chromatography, with the petroleum ether-acetone of volume ratio respectively 10:1,8:1 and 6:1 for washing
De-agent gradient elution, obtains fraction Fr.3-1, Fr.3-2, Fr.3-3 (4.2g)；
(5) fraction Fr.3-3 is through Sephadex LH-20 pillar layer separation, and the methylene chloride-methanol with volume ratio as 1:1 is as eluant
Isocratic elution, obtains fraction Fr.3-3-1 and Fr.3-3-2 (600mg)；
(6) fraction Fr.3-3-2 is through ODS pillar layer separation, and with volume ratio as 1:9, the methanol-water of 3:7,5:5 and 8:2 is as eluting
Agent gradient elution, obtains fraction Fr.3-3-2-1, Fr.3-3-2-2, Fr.3-3-2-3 and Fr.3-3-2-4 (500mg)；
(7) fraction Fr.3-3-2-4 separates through silica gel preparative thin layer chromatography, and the dichloromethane-acetone with volume ratio as 1:1 is for launching
Agent is prepared, and obtains compound 2 (8mg)；
(8) fraction Fr.4 separates through silica gel column chromatography, with volume ratio as 80:1, the chloroform of 40:1,20:1,10:1 and 5:1-
Acetone is eluent gradient eluting, obtains fraction Fr.4-1, Fr.4-2 (2g), Fr.4-3, Fr.4-4 (1.5g) and Fr.4-5 (1.7
g)；
(9) fraction Fr.4-2 is through preparing HPLC chromatogram, and the methanol-water with volume ratio as 7:3 is flowing phase, is purified,
Obtain compound 4 (19mg)；
(10) fraction Fr.4-4 is through preparing HPLC chromatogram, and the methanol-water with volume ratio as 7:3 is flowing phase, is purified,
Obtain compound 5 (4mg)；
(11) fraction Fr.4-5 is flowing phase through ODS pillar layer separation, the methanol-water with volume ratio as 7:3, is purified,
Obtain fraction Fr.4-5-1, Fr.4-5-2 (800mg)；
(12) fraction Fr.4-5-2 is through preparing HPLC chromatogram, and the methanol-water with volume ratio as 7:3 is flowing phase, is purified,
Obtain compound 1 (19mg) and compound 3 (6mg).
Physical chemistry and the constant of each compound are as follows:
Compound 1: unformed powder；UV(MeOH)λmax(logε)218(4.0)nm；IR
(KBr)νmax3396,2921,2851,1740,1711,1683,1647,1467,1384,1229cm-1；CD(MeOH)
Nm (Δ ε) 254 (+1.7), 329 (-0.9)；HRESIME m/z 581.2727[M+Na]+(calcd for C31H42O9Na,
581.2727) molecular formula, determining compound 1 is C31H42O9；1H (400MHz, pyridine-d5) and13C-NMR(100
MHz, pyridine-d5) data are shown in Table 1 and 2.
Compound 2: unformed powder；UV(MeOH)λmax(logε)226(3.7)nm；IRνmax
(KBr) 3395,2920,2849,1646,1469,1384,1121cm-1；CD (MeOH) nm (Δ ε) 255 (+1.5),
331(-0.1)；HRESIME m/z 583.2885[M+Na]+(calcd for C31H44O9Na, 583.2883), determine compound 2
Molecular formula be C30H40O8；1H (400MHz, pyridine-d5) and13C-NMR (100MHz, pyridine-d5) data are shown in
Table 1 and 2.
Compound 3: unformed powder；UV(MeOH)λmax(logε)218(3.9)nm；IR
(KBr)νmax3398,2920,2850,1760,1655,1467,1385,1133cm-1；CD(MeOH)nm(Δε)252
(+1.7), 333 (-1.0)；HRESIME m/z 525.2461[M+Na]+(calcd for C28H38O8Na, 525.2464), determine
The molecular formula of compound 3 is C28H38O8；1H (400MHz, pyridine-d5) and13C-NMR (100MHz, pyridine-d5)
Data are shown in Table 1 and 2.
Compound 4: unformed powderUV(MeOH)λmax(logε)216(4.2)nm；IR(KBr)
νmax3398,2921,2850,1681,1647,1467,1384,1129cm-1；CD (MeOH) nm (Δ ε) 252 (+4.0),
332(-1.9)；HRESIME m/z 537.2830[M+Na]+(calcd for C30H42O7Na, 537.2828), determine compound
The molecular formula of 4 is C30H42O7；1H (400MHz, pyridine-d5) and13C-NMR (100MHz, pyridine-d5) data
It is shown in Table 1 and 2.
Compound 5: unformed powder；UV(MeOH)λmax(logε)224(3.7)nm；
UV(MeOH)λmax(logε)224(4.0)nm；IR(KBr)νmax3395,2921,2850,1760,1647,1467,
1384,1133cm-1；CD (MeOH) nm (Δ ε) 256 (+1.4), 333 (-0.4)；HRESIME m/z 511.2671[M+Na]+
(calcd for C28H40O7Na, 511.2672), determine that the molecular formula of compound 5 is C30H40O8；1H (400MHz, pyridine-d5)
With13C-NMR (100MHz, pyridine-d5) data are shown in Table 1 and 2.
Table 1 compound 1-5 hydrogen modal data
Note: a, 400MHz, pyridine-d5。
The carbon modal data of table 2 compound 1-5
Note: a, 400MHz, pyridine-d5。
The structure of each compound is:
Embodiment 2
The extracting method of withanolide compounds, comprises the steps:
(1) with bitter dry stem and leaf as raw material, the volume fraction adding raw material 8 mass times is 80% ethanol water, backflow
Extract 3 times, extract 2 hours every time, merge and obtain extracting solution, decompression and solvent recovery, after concentration, obtain total extractum；
(2) total extractum is distributed in the water of 5 mass times, extracts with equal-volume petroleum ether and ethyl acetate successively, acetic acid
Ethyl ester extract decompression and solvent recovery, obtains ethyl acetate layer extractum；
(3)-(12) are with embodiment 1 (3)-(12).
Embodiment 3
The extracting method of withanolide compounds, comprises the steps:
(1) with bitter dry stem and leaf as raw material, the volume fraction adding raw material 10 mass times is 60% ethanol water, backflow
Extract 3 times, extract 2 hours every time, merge and obtain extracting solution, decompression and solvent recovery, after concentration, obtain total extractum；
(2) total extractum is distributed in the water of 10 mass times, extracts with equal-volume petroleum ether and ethyl acetate successively, acetic acid
Ethyl ester extract decompression and solvent recovery, obtains ethyl acetate layer extractum；
(3)-(12) are with embodiment 1 (3)-(12).
Embodiment 4
Withanolide compounds suppression mouse macrophage RAW 264.7 discharges the active testing of nitric oxide (NO)
Mouse macrophage RAW 264.7 (ATCC) be incubated at 10% heat inactivation (56 DEG C, 30min) hyclone (Gibco,
USA), 100U/mL penicillin sodium (Gibco, USA), the RPMI 1640 of 100 μ g/mL streptomycin (Gibco, USA)
In (Gibco, USA) culture fluid, 37 DEG C, 5%CO2Constant incubator in hatch growth.Due to NO extremely unstable,
Nitrito-(NO quickly it is metabolized in cell culture supernatant2 -), therefore use Griess method to measure NO in sample2 -Concentration
As the index weighing NO level.Griess reagent A: 0.1%N-naphthodiamide hydrochlorate (naphthylethylene diamine
Dihydrochloride) soluble in water；Griess reagent B:1% P-aminobenzene-sulfonamide (sulphanilamide) is dissolved in 5%H3PO4
In.Use front equal-volume mix reagent A and B.With RPMI RPMI-1640, RAW 264.7 cell is diluted to 5 × 105
Cells/mL concentration, is inoculated in 96 porocyte culture plates, and every hole adds 200100 μ L cell suspending liquids.CO2In incubator
After cultivating 1h, every hole adds lipopolysaccharide (lipopolysaccharide, LPS) (Sigma, JPN) (final concentration 1 μ g/mL)
The test sample 0.4 μ L of variable concentrations dissolved with DMSO, set simultaneously LPS group (add LPS, but be added without test sample,
Suppression ratio to NO release is 0%) and blank group (it is added without LPS and test sample, only adds 0.4 μ L DMSO,
Suppression ratio to NO release is 100%), each sample sets 4 parallel holes.At 37 DEG C, 5%CO2Constant incubator
Middle cultivation 24h, draws 100 μ L culture fluid supernatants in ELISA Plate, centrifugal (1000 × g, 4 DEG C, 3min), add 100
μ L Griess reagent, room temperature lucifuge reaction 10min, measure light absorption value at its 540nm in microplate reader.With concentration be respectively 1,
5, the NaNO of 10,50 μm ol/L2Draw standard curve, according to NaNO2NO in standard curve cell culture supernatant2 -'s
The suppression ratio that NO is discharged by concentration and then calculating test sample.
The suppression NO of table 3 compound discharges result
The anti-inflammatory drug of the compositions containing compound of the present invention can be to be applicable to the application forms such as oral or injection, such as,
Technology routinely, adds pharmaceutically acceptable carrier and/or excipient makes tablet, capsule, powder, syrup, injection etc..
Compound has pharmacologically active, and therefore, the compositions containing this compound also has pharmacologically active.
The explanation of above example is only intended to help to understand method and the central idea thereof of the present invention.It should be pointed out that, for ability
For the those of ordinary skill in territory, under the premise without departing from the principles of the invention, it is also possible to the present invention is carried out some improvement and repaiies
Decorations, these improve and modify the protection also falling into the claims in the present invention.
The withanolide compounds of the present invention, the extract containing withanolide compounds, group containing withanolide compounds
Compound can prepare the medicine for the treatment of metabolism of nitric oxide exception associated diseases.
Its disease being associated includes: systemic inflammatory response syndrome, hypertension, cerebral thrombosis, heart failure, liver cirrhosis, class
Rheumatic arthritis, osteoarthritis, joint of vertebral column inflammation, inflammatory bowel, acute pancreatitis, peritonitis, cholecystitis, appendicitis,
Diabetes, systemic lupus erythematosus (sle), dermatitis flesh, psoriasis, acute myeloid leukaemia, Parkinson's disease, presenile dementia, press down
Strongly fragrant disease, septicemia, chronic obstructive pneumonia, asthma, acute pancreatitis, central nervous system injury etc..Secondly, NO Developmental and Metabolic Disorder
Also relevant with the hypertrophy of canceration and cancerous tissue, the NO of high concentration also can suddenly change and tumor by modificator gene, and above-claimed cpd can suppress
NO discharges, thus plays antineoplastic action.The tumor example being suitable for includes but not limited to: various entity tumors and leukemia,
Such as pulmonary carcinoma, hepatocarcinoma, cancer of pancreas, gastric cancer, osteocarcinoma, esophageal carcinoma, carcinoma of prostate, colon cancer, ovarian cancer, bladder cancer, uterus
Neck cancer, melanoma, carcinoma of testis, bronchogenic carcinoma, renal cell carcinoma, cancer of biliary duct, choriocarcinoma, glioma, neural fibre
Dimension tumor, fibrosarcoma, lymphangioma etc..
Claims (8)
1. withanolide compounds, is characterized in that the structure with formula (I):
Wherein:
R1For OH or OCH3；
R2For OH or H；
R3For OH or OAc；
R4For H；R5For H or OH；Or R4And R5For
R6For H or OH.
2. compound as claimed in claim 1, it is characterised in that described structural formula of compound is:
3. the extracting method of compound described in claim 1 or 2, it is characterised in that comprise the steps:
(1) with bitter dry stem and leaf as raw material, the volume fraction adding raw material 8-10 mass times is 60%-80% ethanol water,
Reflux, extract, 2-3 time, extracts 2-3 hour every time, merges and obtains extracting solution, decompression and solvent recovery, obtains total extractum after concentration；
(2) total extractum is distributed in the water of 5-10 mass times, extracts by petroleum ether and ethyl acetate successively, ethyl acetate
Extract decompression and solvent recovery, obtains ethyl acetate layer extractum；
(3) ethyl acetate layer extractum separates through silica gel column chromatography, is respectively the two of 100:1,50:1,30:1 and 15:1 with volume ratio
Chloromethanes-methanol is eluent gradient eluting, obtains fraction Fr.1, Fr.2, Fr.3 and Fr.4；
(4) fraction Fr.3 separates through silica gel column chromatography, with the petroleum ether-acetone of volume ratio respectively 10:1,8:1 and 6:1 for washing
De-agent gradient elution, obtains fraction Fr.3-1, Fr.3-2, Fr.3-3；
(5) fraction Fr.3-3 is through Sephadex LH-20 pillar layer separation, and the methylene chloride-methanol with volume ratio as 1:1 is as eluant
Isocratic elution, obtains fraction Fr.3-3-1 and Fr.3-3-2；
(6) fraction Fr.3-3-2 is through ODS pillar layer separation, and with volume ratio as 1:9, the methanol-water of 3:7,5:5 and 8:2 is as eluting
Agent gradient elution, obtains fraction Fr.3-3-2-1, Fr.3-3-2-2, Fr.3-3-2-3 and Fr.3-3-2-4；
(7) fraction Fr.3-3-2-4 separates through silica gel preparative thin layer chromatography, and the dichloromethane-acetone with volume ratio as 1:1 is for launching
Agent is prepared, and obtains compound 2；
(8) fraction Fr.4 separates through silica gel column chromatography, with volume ratio as 80:1, the chloroform of 40:1,20:1,10:1 and 5:1-
Acetone is eluent gradient eluting, obtains fraction Fr.4-1, Fr.4-2, Fr.4-3, Fr.4-4 and Fr.4-5；
(9) fraction Fr.4-2 is through preparing HPLC chromatogram, and the methanol-water with volume ratio as 7:3 is flowing phase, is purified,
Obtain compound 4；
(10) fraction Fr.4-4 is through preparing HPLC chromatogram, and the methanol-water with volume ratio as 7:3 is flowing phase, is purified,
Obtain compound 5；
(11) fraction Fr.4-5 is flowing phase through ODS pillar layer separation, the methanol-water with volume ratio as 7:3, is purified,
Obtain fraction Fr.4-5-1, Fr.4-5-2；
(12) fraction Fr.4-5-2 is through preparing HPLC chromatogram, and the methanol-water with volume ratio as 7:3 is flowing phase, is purified,
Obtain compound 1 and compound 3.
4. the withanolide compounds of claim 1 and 2 application in preparation suppression cell release NO medicine.
5. comprise the bitter extract of withanolide class.
6. the bitter extract of claim 5 application in preparation suppression cell release NO medicine.
7. a pharmaceutical composition, is characterized in that comprising withanolide compounds or its pharmaceutically acceptable salt, and pharmaceutically
Acceptable carrier and/or excipient.
8. the pharmaceutical composition of claim 7 application in preparation suppression cell release NO medicine.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710445342.8A CN107056869B (en) | 2016-05-20 | 2016-05-20 | A kind of withanolide class compound and extracting method and application |
| CN201610341609.4A CN105949266B (en) | 2016-05-20 | 2016-05-20 | Withanolide class compound and extracting method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610341609.4A CN105949266B (en) | 2016-05-20 | 2016-05-20 | Withanolide class compound and extracting method and application |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710445342.8A Division CN107056869B (en) | 2016-05-20 | 2016-05-20 | A kind of withanolide class compound and extracting method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105949266A true CN105949266A (en) | 2016-09-21 |
| CN105949266B CN105949266B (en) | 2018-01-12 |
Family
ID=56910594
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610341609.4A Active CN105949266B (en) | 2016-05-20 | 2016-05-20 | Withanolide class compound and extracting method and application |
| CN201710445342.8A Active CN107056869B (en) | 2016-05-20 | 2016-05-20 | A kind of withanolide class compound and extracting method and application |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710445342.8A Active CN107056869B (en) | 2016-05-20 | 2016-05-20 | A kind of withanolide class compound and extracting method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN105949266B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110907585A (en) * | 2019-11-18 | 2020-03-24 | 陕西嘉禾生物科技股份有限公司 | Thin-layer detection method for identifying adulteration of Withania somnifera root extract |
| CN111718393A (en) * | 2020-06-08 | 2020-09-29 | 天津中医药大学 | Withanolide compound and application thereof |
| CN112979740A (en) * | 2021-03-08 | 2021-06-18 | 沈阳药科大学 | Withanolide I compound and extraction method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101422467A (en) * | 2007-11-02 | 2009-05-06 | 华东理工大学 | Immunosuppressant containing Withanolide type compound |
-
2016
- 2016-05-20 CN CN201610341609.4A patent/CN105949266B/en active Active
- 2016-05-20 CN CN201710445342.8A patent/CN107056869B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101422467A (en) * | 2007-11-02 | 2009-05-06 | 华东理工大学 | Immunosuppressant containing Withanolide type compound |
Non-Patent Citations (1)
| Title |
|---|
| YU-ZHOU GUAN ET AL.: "Withanolides from physalis minima and their inhibitory effects on nitric oxide production", 《 STEROIDS》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110907585A (en) * | 2019-11-18 | 2020-03-24 | 陕西嘉禾生物科技股份有限公司 | Thin-layer detection method for identifying adulteration of Withania somnifera root extract |
| CN110907585B (en) * | 2019-11-18 | 2022-03-08 | 陕西嘉禾生物科技股份有限公司 | Thin-layer detection method for identifying adulteration of Withania somnifera root extract |
| CN111718393A (en) * | 2020-06-08 | 2020-09-29 | 天津中医药大学 | Withanolide compound and application thereof |
| CN111718393B (en) * | 2020-06-08 | 2022-05-24 | 天津中医药大学 | Withanolide compound and application thereof |
| CN112979740A (en) * | 2021-03-08 | 2021-06-18 | 沈阳药科大学 | Withanolide I compound and extraction method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107056869B (en) | 2019-07-16 |
| CN105949266B (en) | 2018-01-12 |
| CN107056869A (en) | 2017-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Lignans from the heartwood of Streblus asper and their inhibiting activities to hepatitis B virus | |
| Tian et al. | A review of the ethnopharmacology, phytochemistry, pharmacology and toxicology of Fructus Gardeniae (Zhi-zi) | |
| CN104861015A (en) | Synergistic clean extraction method of effective components in licorice root | |
| CN105017357A (en) | Polyphenol flavonoid and preparing method and application of polyphenol flavonoid | |
| Li et al. | Anti-inflammatory terpenes from Schefflera rubriflora CJ Tseng & G. Hoo with their TNF-α and IL-6 inhibitory activities | |
| Yuan et al. | Anti-inflammatory and analgesic activities of Neolamarckia cadamba and its bioactive monoterpenoid indole alkaloids | |
| CN105949266A (en) | Withana lactide compound, method for extracting same and application of withana lactide compound | |
| CN106008502A (en) | Alkaloid compounds with novel skeletons in purslane and extraction and separation method thereof | |
| Hu et al. | Lignans and terpenoids from Gaultheria leucocarpa var. yunnanensis and their anti-inflammatory and antioxidant activities | |
| CN106008641A (en) | Withania somnifera lactide compound, method for extracting same and application of withania somnifera lactide compound | |
| CN105949272A (en) | With a-physalin Y, method for extracting same and application of with a-physalin Y | |
| CN102219782B (en) | Method for extracting and separating viterxin and isovitexin from natural product | |
| CN111574531A (en) | Terpene phenolic compound NO85, and preparation method and application thereof | |
| CN102048714A (en) | Application of diphenol compounds in preparation of anti-complement medicaments | |
| WO2017215679A2 (en) | Pharmaceutical composition of chlorambucil and medical use thereof to counter depression | |
| CN108948040B (en) | Gilmaxane type sesquiterpene compound extracted from herba Centellae and application thereof | |
| CN106008657B (en) | Ku Zhi bitter principles I and extracting method and purposes | |
| Dávid et al. | Jacaranone derivatives with antiproliferative activity from Crepis pulchra and relevance of this group of plant metabolites. Plants 2022; 11: 782 | |
| CN105837592A (en) | Phloroglucinolo abietane diterpenoid compound, preparation method thereof and medicinal application | |
| CN109180632A (en) | A kind of noval chemical compound isolated from tripterygium wilfordii and preparation method thereof and medical usage | |
| CN107082780A (en) | A kind of alkaloid with the parallel isoquinoline structure of pyrroles and preparation method and application | |
| CN116903578B (en) | Phenolic acid compound in Glechoma hederacea as well as extraction and separation method and application thereof | |
| CN117304032B (en) | Steroid sapogenin compound in radix clinopodii, and preparation method and application thereof | |
| CN110256511B (en) | Sulfur-containing spiro ketal sesquiterpene compound and application thereof and application of sulfur-containing spiro ketal sesquiterpene compound | |
| CN109748945A (en) | Four kinds of Gypenoside L and Gypenoside LI acetyl derivatives and its purposes for preparing anti-tumor drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |